SRSF1 as a promising biomarker and key player in the pathogenesis of Alzheimer's disease

‑induced mouse model, SRSF1 expression was upregulated in the hippocampus and cerebral cortex. Moreover, in patients with AD, SRSF1 mRNA levels in peripheral blood mononuclear cells showed a strong negative correlation with mini‑mental state examination and Montreal cognitive assessment scores and a positive correlation with clinical dementia rating scores, indicating a notable association between elevated SRSF1 expression and cognitive decline. Furthermore, SRSF1 levels were positively associated with plasma levels of p‑tau217, p‑tau181 and glial fibrillary acidic protein. These findings underscore the strong association between SRSF1 and AD pathology. The newly identified genes, particularly SRSF1, show potential as candidate biomarkers of AD progression and may provide insights into AD pathogenesis, but require further validation in a larger prospective cohort.